1. Home
  2. Analysis
  3. Neupro
  4. Application-site-exfoliation

Neupro and Application site exfoliation - a phase IV clinical study of FDA data

Summary:

Application site exfoliation is reported as a side effect among people who take Neupro (rotigotine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Entacapone,.

The phase IV clinical study analyzes which people have Application site exfoliation when taking Neupro. It is created by eHealthMe based on reports of 11,313 people who have side effects when taking Neupro from the FDA, and is updated regularly.

What is Neupro?

Neupro has active ingredients of rotigotine. It is often used in parkinson's disease. eHealthMe is studying from 11,393 Neupro users. Check the latest studies of Neupro.

What is Application site exfoliation?

Application site exfoliation (application site removal of the oldest dead skin cells on the skin's outermost surface) is found to be associated with 176 drugs and 353 conditions by eHealthMe. Check the latest studies of Application site exfoliation.

On Aug, 02, 2026

11,313 people reported to have side effects when taking Neupro.
Among them, 12 people (0.11%) have Application site exfoliation.

Could Neupro cause Application site exfoliation?

Among these 12 people:

How long have people been on Neupro when they have Application site exfoliation? *

  • < 1 month: 33.33 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 16.67 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 16.67 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Application site exfoliation when taking Neupro? *

  • female: 66.67 %
  • male: 33.33 %

What is the age of people who have Application site exfoliation when taking Neupro? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

What are other drugs people take besides Neupro? *

  1. Requip: 1 person, 8.33%
  2. Nabumetone: 1 person, 8.33%
  3. Maxzide: 1 person, 8.33%
  4. Lexapro: 1 person, 8.33%
  5. Gemfibrozil: 1 person, 8.33%
  6. Evoxac: 1 person, 8.33%
  7. Entacapone: 1 person, 8.33%

What are other side effects people have besides Application site exfoliation? *

  1. Application Site Pruritus (application site severe itching of the skin): 6 people, 50.00%
  2. Application Site Erythema (redness of the skin at application site): 5 people, 41.67%
  3. Application Site Irritation: 4 people, 33.33%
  4. Nausea (feeling of having an urge to vomit): 2 people, 16.67%
  5. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 2 people, 16.67%
  6. Application Site Scar: 2 people, 16.67%
  7. Application Site Reaction: 2 people, 16.67%
  8. Application Site Rash: 2 people, 16.67%
  9. Skin Discoloration: 1 person, 8.33%
  10. Pain: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Neupro and have Application site exfoliation?

- Check whether Application site exfoliation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neupro:

Application site exfoliation treatments and more:

How severe was Application site exfoliation and when was it recovered:

Expand to all the drugs that have ingredients of rotigotine:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neupro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site exfoliation:

Browse all the conditions that are associated with Application site exfoliation:

How the study uses the data?

The study uses data from the FDA. It is based on rotigotine (the active ingredients of Neupro) and Neupro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.